Trastuzumab pamirtecan slows breast cancer progression but raises interstitial lung disease concerns
BioNTech's breast cancer drug meets its Phase 3 endpoint but serious lung toxicity raises concerns. Explore the results and approval outlook.
Pharma & Biotech
Pharma & Biotech
Pfizer’s Lyme vaccine showed 73% efficacy, but missed a statistical hurdle. What comes next?
Pfizer will present 57 infectious disease abstracts at IDWeek 2026, including Phase 3 Lyme vaccine findings, new pediatric pneumococcal data and real-world RSV effectiveness studies. The programme highlights pipeline progress while leaving important regulatory and clinical questions unresolved.
Pharma & Biotech
BioNTech’s gotistobart delivered 18.5-month survival. Can the pivotal trial confirm it?
BioNTech’s gotistobart posts 18.5-month median survival versus 10 months with docetaxel as the pivotal Phase 3 stage continues.
Pharma & Biotech
Why DualityBio’s China filing for trastuzumab pamirtecan matters in the HER2 breast cancer ADC race
DualityBio’s trastuzumab pamirtecan has entered China review for HER2-positive breast cancer. Read what this filing could change next.
Pharma & Biotech
Genmab ends acasunlimab trials: What it signals about bispecific immunotherapy risk
Genmab ends development of acasunlimab to focus on EPKINLY, petosemtamab, and Rina-S. Find out what this shift means for 4-1BB bispecifics today.
Features & Analysis
Why are “retired proteins” the hottest new targets in cancer immunotherapy research?
Few ideas have captivated both the scientific imagination and biotech investment flows quite like the cancer vaccine. For decades, the industry narrative was full of hope—and disappointment. The graveyard of failed trials stretches from Dendreon’s Provenge to once-hyped peptide and dendritic cell platforms. For every announcement of an “immune breakthrough,” there seemed to be a